PT-141 is the one peptide in this whole conversation that actually has a green-light from the FDA. Generic name bremelanotide, brand name Vyleesi, approved June 21, 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. That's a real Phase III trial, real regulatory file, real prescription product. The catch: approval is for women only, the response rates are modest, and the men using it for ED or "the libido peptide" are fully off-label. Here's what the evidence actually says, and where the story gets more complicated than the headlines suggest.
Key Takeaways
- —Bremelanotide (Vyleesi/PT-141) got FDA approval June 2019 for HSDD in premenopausal women — still the only peptide cleared for any sexual dysfunction indication.
- —Mechanism: melanocortin-4 receptor (MC4R) agonist working centrally on CNS desire pathways, not vascular dilation like sildenafil or tadalafil.
- —Phase III RECONNECT: 25% on bremelanotide vs 17% placebo hit a meaningful bump in satisfying sexual events; 50% vs 35% reported less distress (PMC, 2019).
- —Approved dose: 1.75 mg subq, 45 minutes before sex, max once per 24 hours.
- —Off-label use in men is in active Phase II for PDE5i non-responders (Palatin Technologies, 2024–2025).
PT-141 came out of a tanning-drug program that produced an unexpected side effect. Bremelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH), descended from melanotan II (MT-II). When researchers at the University of Arizona were testing MT-II as a tanning agent in the 1990s, male participants kept getting spontaneous erections. That redirected the whole program toward sexual function, and PT-141 is the candidate that survived clinical development.
The original formulation was a nasal spray. That got scrapped when it caused transient blood pressure spikes that the FDA wasn't going to approve. The subq injection at 1.75 mg became the route that made it through, with a label warning to avoid it in people with cardiovascular disease or uncontrolled hypertension.
This is the piece most people miss. PDE5 inhibitors and PT-141 aren't competing tools, they're solving different problems. Sildenafil (Viagra), tadalafil (Cialis), and the rest work peripherally. They block phosphodiesterase type 5 in smooth muscle, raise cGMP, and dilate the vasculature feeding genital tissue. They need arousal to already be there. They don't generate it.
Bremelanotide hits the CNS directly. It's a melanocortin-4 receptor (MC4R) agonist, and those receptors sit in hypothalamic and limbic pathways tied to sexual motivation and arousal. Animal models show MC4R activation drives proceptive behaviours, the approach and solicitation that comes before the physical response. In humans the proposed action is modulating desire and arousal at the neural level, upstream of any vascular event.
So the layers are different. PDE5 inhibitors handle the hydraulics of getting an erection. PT-141 handles the motivational signal that kicks the whole sequence off. For HSDD, where the defining feature is an absent desire signal causing real distress, PDE5 inhibitors aren't the right tool. Melanocortin pathway modulation is.
The Phase III RECONNECT trial enrolled 1,247 premenopausal women with HSDD diagnosed by the Female Sexual Dysfunction Index (FSFI). Participants used bremelanotide 1.75 mg subq or placebo on demand over 52 weeks.
Primary endpoints:
What to make of the numbers: The absolute efficacy signal is small. The FDA cleared it on statistical significance across both coprimary endpoints, a clean safety profile, and a real unmet need (no other approved drug for HSDD in women existed). The 25% vs 17% split on SSEs translates to roughly NNT 12 for one person to benefit on that endpoint.
The long-term safety and efficacy analysis in Fertility and Sterility (2019) reported consistent, statistically significant improvement in desire and distress outcomes over 52 weeks, with the safety profile mostly transient nausea (40.1% vs 1.2% placebo) and flushing (20.4% vs 3.4% placebo) (PMC, 2019).
FDA approval covers HSDD in premenopausal women. That's it. Men running PT-141 are using it off-label for ED or, more often, for the desire side rather than the mechanics.
2024 open-label pilot: 21 men with various sexual dysfunctions got subq bremelanotide. 80% reported being more satisfied with sex on at least two occasions. No control group, so this is an observational report, not a trial.
Palatin Technologies Phase II (2024–2025): The most rigorous active human study in men. Palatin is testing a co-formulation of bremelanotide and a PDE5 inhibitor in a single subq injection for men who don't respond to PDE5 inhibitors alone. Topline data was expected late 2024, with Phase III planning in 2025 if the readout holds. This would be the first RCT-grade evidence in men.
Older ED data: Earlier bremelanotide work in men, pre-2006 when the nasal formulation was still alive, showed dose-dependent improvements in erectile response in both psychogenic and organic ED. No placebo control, but clear dose-response curves.
Approved dose (women, HSDD):
Off-label research protocols (men):
The nausea problem: Nausea is the dose-limiting side effect for most users, hitting 40% of women in RECONNECT vs 1.2% on placebo. People typically describe it kicking in 30–60 minutes after the subq pin and clearing within 2 hours. Ondansetron taken ahead of time helps. The 0.5–1 mg titration is the real-world workaround if a full dose puts you on the floor.
| Parameter | Approved (Women) | Research (Men) |
|---|---|---|
| Dose | 1.75 mg SubQ | 1–2 mg SubQ |
| Timing | 45 min before | 30–60 min before |
| Frequency | Max 1×/24h; ~8×/month | Same caution applied |
| Main adverse effect | Nausea (40%), flushing (20%) | Similar profile |
Transient BP elevation: Bremelanotide bumps systolic by about 6 mmHg and diastolic by about 4 mmHg on average, peaking 30–40 minutes post-injection and resolving within 12 hours. This is the same signal that killed the nasal spray. The subq formulation still does it, which is why the label contraindicates it in people with cardiovascular disease or uncontrolled hypertension.
Label warnings: Contraindicated in known CV disease (arrhythmias, coronary artery disease, stroke history, uncontrolled hypertension). Don't combine with alcohol, which makes the nausea worse.
No hormonal effects: Unlike GHRPs or GH secretagogues, bremelanotide doesn't touch the HPG or HPA axis at therapeutic doses. Testosterone, estrogen, LH, FSH, cortisol, ACTH all unchanged.
What people actually report: Nausea (described as "a half hour of feeling carsick"), flushing (warm face, sometimes pink chest), occasional headache, and the BP bump that's measurable but usually unnoticeable. Most of it lands within the first hour and is gone by hour two.
PT-141's FDA-approved status means it can be legally prescribed, but that doesn't mean every source selling it is legitimate, or that every formulation is the same molecule at the same purity. The Next Pep peptide library covers bremelanotide's MC4R mechanism, pharmacokinetics, clinical trial history, and the differences between the FDA-approved Vyleesi formulation and off-label research variants in one verified reference.
Use the comparison tool to put PT-141 next to other compounds you're researching, especially if you're weighing its mechanism against PDE5 inhibitors or other melanocortin-pathway compounds. Next Pep is the neutral, non-commercial source for this data, no vendor conflict, just published evidence.
Yes. Vyleesi is the FDA-approved brand name for bremelanotide (PT-141), 1.75 mg subq, for treating HSDD in premenopausal women. PT-141 is the research name for the same molecule.
PDE5 inhibitors like sildenafil (Viagra) work peripherally. They open up blood flow to genital tissue but need arousal to already be present. Bremelanotide acts centrally through melanocortin-4 receptors in the brain, modulating desire and arousal at the neural level. It isn't primarily a vascular drug.
The big ones are transient nausea (40% in Phase III), flushing (20%), and a mild transient BP bump. Nausea typically peaks 30–60 minutes after the subq pin and clears within 2 hours. Pre-dosing ondansetron helps. The BP signal is why it's contraindicated in cardiovascular disease.
FDA approval is women only. Small pilot studies and off-label use in men have been published, with improvements in desire and erectile function. Palatin Technologies is running a Phase II in PDE5-inhibitor non-responders in 2024–2025. As of 2026, no completed RCT in men.
Clinical reports suggest additive or synergistic effects, and Palatin's Phase II is specifically testing a bremelanotide + PDE5 inhibitor combo in one injection. Stacking the two on your own without medical supervision isn't a great idea given the BP profile of both classes.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.